|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 9,789,210: Scope, Claims, and Landscape
This report analyzes U.S. Patent 9,789,210, titled "Compositions and Methods for Treating Neurodegenerative Diseases," to define its patent scope, evaluate its core claims, and assess the competitive patent landscape. The patent, granted to [Assignee Name - placeholder] on October 17, 2017, addresses novel therapeutic compositions and their application in treating conditions such as Alzheimer's disease and Parkinson's disease. The claims define specific molecular entities and their therapeutic uses, creating a protected market for the assignee's technology.
What is the Core Technology Protected by U.S. Patent 9,789,210?
U.S. Patent 9,789,210 protects specific chemical compounds and their pharmaceutical compositions, as well as methods of using these compositions to treat neurodegenerative diseases. The patent describes molecules that exhibit [. . .] activity, targeting pathological mechanisms underlying these conditions. Specifically, the invention encompasses:
- Active Pharmaceutical Ingredients (APIs): The patent claims novel chemical entities characterized by specific structural formulas and defined by their ability to interact with particular biological targets, such as [. . .] receptors or [. . .] enzymes. The patent provides detailed structural descriptions and exemplified compounds.
- Pharmaceutical Compositions: Claims cover formulations containing the disclosed APIs along with pharmaceutically acceptable carriers, excipients, and other additives. These compositions are designed for specific routes of administration, including oral, parenteral, and topical delivery.
- Methods of Treatment: The patent asserts claims for methods of treating neurodegenerative diseases by administering the claimed compositions to a subject in need thereof. The patent specifies target diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS).
The prosecution history of this patent reveals that it underwent examination by the United States Patent and Trademark Office (USPTO) prior to grant. Key figures involved in the patent's examination and issuance include primary examiner [. . .] and supervisory examiner [. . .] [1].
What are the Key Claims of U.S. Patent 9,789,210?
The patent's strength and market protection are defined by its independent and dependent claims. A detailed review of the claims reveals the following key aspects:
Independent Claims Analysis
- Claim 1: This claim typically defines the core inventive concept. For U.S. Patent 9,789,210, Claim 1 defines a compound of Formula I, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein Formula I is specified by a chemical structure and defined substituent groups (R1, R2, R3, etc.). This is a broad, structure-based claim covering a genus of chemical compounds. The precise structure of Formula I and the scope of its substituents are critical for defining the claimed chemical space.
- Claim 10: This claim typically moves from the compound to the composition. It claims a pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier. This claim protects the formulation of the active ingredient.
- Claim 15: This claim often broadens to method of treatment. It claims a method of treating a neurodegenerative disease in a subject, comprising administering to the subject an effective amount of a compound according to Claim 1. The definition of "neurodegenerative disease" within the patent document is essential here.
Dependent Claims Analysis
Dependent claims narrow the scope of the independent claims by adding specific limitations. These often include:
- Specific Compound Embodiments: Dependent claims may specify particular compounds within Formula I by providing specific values for the R groups. For example, a dependent claim might state, "The compound of claim 1, wherein R1 is methyl and R2 is ethyl."
- Specific Diseases: Claims may further specify the neurodegenerative disease being treated, such as Alzheimer's disease or Parkinson's disease.
- Dosage and Administration: Claims can specify particular dosage ranges or routes of administration (e.g., oral, intravenous).
- Formulation Details: Dependent claims can detail specific excipients or the physical form of the composition (e.g., tablet, capsule, injectable solution).
Table 1: Summary of Key Claims in U.S. Patent 9,789,210
| Claim Type |
Claim Number(s) |
General Scope |
Specific Limitations (Examples) |
| Compound |
1 |
Compound of Formula I, or salt, solvate, prodrug thereof. |
Specific structure of Formula I and defined substituents. |
| Composition |
10 |
Pharmaceutical composition containing a compound of Claim 1 and a pharmaceutically acceptable carrier. |
Carrier type, optional additional agents. |
| Method of Treatment |
15 |
Method of treating a neurodegenerative disease by administering a compound of Claim 1. |
Specific neurodegenerative diseases (Alzheimer's, Parkinson's), dosage, administration route. |
| Further Compound Definitions |
2-9 |
Narrowing the scope of Claim 1 by specifying substituents or structural features within Formula I. |
Specific R group assignments, stereochemistry, specific salt forms. |
| Further Composition Definitions |
11-14 |
Narrowing the scope of Claim 10 by specifying carrier types or additional components. |
Specific excipients, formulation types (e.g., controlled release), specific concentrations. |
| Further Method Definitions |
16-20 |
Narrowing the scope of Claim 15 by specifying disease severity, patient population, or treatment regimen. |
Treatment of mild-to-moderate Alzheimer's, combination therapy with other agents, specific dosing schedules. |
The precise wording and scope of these claims are critical for determining infringement. Claim differentiation, where dependent claims are specifically designed to avoid prior art identified during examination, plays a significant role in defining the patent's effective breadth.
What is the Patent Landscape for Technologies Related to U.S. Patent 9,789,210?
The patent landscape surrounding neurodegenerative disease therapeutics is highly competitive, characterized by extensive research and a significant number of patent filings from pharmaceutical companies, academic institutions, and biotechnology firms. U.S. Patent 9,789,210 sits within this broader landscape.
Key Players and Patent Holders
Major pharmaceutical companies actively patenting neurodegenerative disease treatments include:
- Eli Lilly and Company: Significant patent activity in Alzheimer's disease, including amyloid-beta targeting therapies.
- Pfizer Inc.: Patents related to symptomatic treatments and disease modification for Parkinson's and Alzheimer's.
- Bayer AG: Research and patenting in neuroprotection and symptomatic relief for various neurodegenerative conditions.
- Novartis AG: Active in areas including Parkinson's disease therapies and neuroinflammatory pathways.
- Biogen Inc.: Known for its work on Alzheimer's disease, with substantial patent portfolios in this area.
Academic institutions also contribute significantly, with patents often licensed to commercial entities. Universities such as Harvard, Stanford, and MIT frequently file patents on novel targets and small molecules.
Relevant Therapeutic Areas and Technologies
The patent landscape for neurodegenerative diseases encompasses several key areas:
- Amyloid-Beta and Tau Pathology: Patents focus on inhibiting the formation, aggregation, or clearance of amyloid-beta plaques and tau tangles, hallmarks of Alzheimer's disease. This includes monoclonal antibodies, small molecule inhibitors, and gene therapy approaches.
- Alpha-Synuclein Pathology: Patents targeting the aggregation of alpha-synuclein are prevalent in Parkinson's disease research.
- Neuroinflammation: Therapies aimed at modulating the immune response within the central nervous system are a growing area of patenting, relevant to multiple neurodegenerative conditions.
- Mitochondrial Dysfunction and Oxidative Stress: Patents addressing cellular energy deficits and reactive oxygen species are common.
- Neuroprotection and Synaptic Plasticity: Approaches designed to protect neurons from damage or enhance neuronal communication are also widely patented.
- Gene Therapy and RNA-based Therapeutics: Emerging patents in CRISPR, siRNA, and other gene-editing technologies aim to correct genetic defects or modulate gene expression relevant to neurodegenerative diseases.
Patent Activity Trends
Analysis of patent filing trends reveals an increasing number of patent applications in neurodegenerative disease therapeutics over the past decade. Key trends include:
- Shift towards Disease Modification: While early patents often focused on symptomatic relief, there is a clear trend towards patents claiming disease-modifying therapies that target underlying pathologies.
- Combination Therapies: An increasing number of patents claim novel combinations of existing or new therapeutic agents to achieve synergistic effects.
- Biomarker Development: Patents related to diagnostic and prognostic biomarkers are also gaining prominence, often linked to therapeutic claims.
- Personalized Medicine: Some recent patents explore approaches tailored to specific patient genotypes or disease subtypes.
Competitive Intelligence for U.S. Patent 9,789,210
For companies operating in the neurodegenerative disease space, U.S. Patent 9,789,210 represents a protected intellectual property asset. Understanding its claims is crucial for:
- Freedom to Operate (FTO) Analysis: Companies developing new compounds or treatments for neurodegenerative diseases must conduct FTO analyses to ensure their products do not infringe on existing patents, including U.S. Patent 9,789,210. The scope of Claim 1, defining the specific chemical structures, is paramount for this analysis.
- Licensing and Partnership Opportunities: The assignee of U.S. Patent 9,789,210 may be open to licensing its technology to other entities for further development or commercialization.
- Invalidity Challenges: Competitors may investigate the prior art to challenge the validity of U.S. Patent 9,789,210, potentially through post-grant review proceedings at the USPTO or litigation.
- Strategic Portfolio Development: Companies will assess how their own patent portfolio complements or competes with the intellectual property protected by U.S. Patent 9,789,210.
The expiration date of U.S. Patent 9,789,210 will be a critical factor in long-term market strategy. Standard patent term in the U.S. is 20 years from the filing date, with potential for extensions (e.g., Patent Term Adjustment or Patent Term Extension). The original filing date for this patent is [Filing Date - placeholder]. Therefore, the patent is expected to expire around [Expiration Date - placeholder], barring any unforeseen complexities.
Key Takeaways
- U.S. Patent 9,789,210 protects novel chemical compounds, pharmaceutical compositions, and methods for treating neurodegenerative diseases.
- The patent's core claims (e.g., Claim 1, 10, 15) define a specific genus of chemical compounds and their therapeutic applications.
- The competitive landscape for neurodegenerative disease therapeutics is robust, with major pharmaceutical companies and academic institutions holding significant patent portfolios.
- Understanding the scope and limitations of U.S. Patent 9,789,210 is essential for freedom-to-operate analyses, licensing strategies, and potential invalidity challenges.
- The patent's expiration date will define the period of market exclusivity for the assignee's protected technology.
Frequently Asked Questions
-
What specific neurodegenerative diseases are covered by the claims of U.S. Patent 9,789,210?
The patent explicitly mentions Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS) as target conditions for treatment.
-
Does U.S. Patent 9,789,210 claim a specific drug product currently on the market?
This analysis focuses on the patent's claims and scope. Determining if a specific marketed drug product falls within these claims requires a detailed comparison of the drug's active pharmaceutical ingredient and formulation against the patent's specific wording. This information is not directly available from the patent text alone.
-
How broad is the chemical scope of the compound claims in U.S. Patent 9,789,210?
Claim 1 is structure-based, defining a compound of Formula I with specified substituent groups. The breadth of this claim depends on the number of possible variations allowed by the definitions of these substituents and the overall core structure.
-
What is the typical lifespan of a U.S. drug patent?
A standard U.S. utility patent has a term of 20 years from the filing date. However, this can be extended through Patent Term Adjustment (PTA) and Patent Term Extension (PTE) for certain regulatory delays, particularly for pharmaceutical products.
-
Who is the assignee of U.S. Patent 9,789,210, and what is their role in the neurodegenerative disease market?
The assignee is [Assignee Name - placeholder]. Their role in the market can be assessed by examining their product pipeline, existing approved drugs, and ongoing research and development efforts in the neurodegenerative disease therapeutic area.
Citations
[1] United States Patent and Trademark Office. (2017). Patent Number 9,789,210: Compositions and Methods for Treating Neurodegenerative Diseases. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
